1371 / 1983
Hyperfractionated or accelerated radiotherapy in head and
neck cancer: a meta-analysis
Bourhis et al. Lancet 2006; 368: 843-854
•
Fifteen trials with 6515 patients included
•
Mainly oropharynx and larynx tumors
•
74% of patients had stage III-IV disease
•
Three categories:
hyperfractionated
accelerated
accelerated with total dose reduction
•
Data were collected for individual patients.